CEEPC/IPM/CMSC - Abstrakt prezentace

(CEEPC/IPM/CMSC 2022 - FrP-42)
Cytokine expression in spontaneous regression of melanoma in Melanoma-bearing Libechov Minipig model

Veronika Cizkova 1,2, Vratislav Horak 1, Jana Cizkova 1,3, Hanadi Ananbeh 1, Petr Vodicka 1, Katerina Vodickova Kepkova 1, Lukas Lacina 4,5, Karolina Strnadova 4,5, Karel Smetana 4,5, Helena Kupcova Skalnikova 1,4 *

  1. Institute of Animal Physiology and Genetics, Czech Academy of Sciences, Libechov, Czech Republic
  2. Faculty of Science, Charles University, Prague, Czech Republic
  3. Faculty of Military Health Sciences, University of Defence, Hradec Kralove, Czech Republic
  4. First Faculty of Medicine, Charles University, Prague, Czech Republic
  5. BIOCEV, First Faculty of Medicine, Charles University, Vestec, Czech Republic


Melanoma is highly malignant skin cancer originating from transformed melanocytes. Interestingly, an immune response to melanoma can be spontaneously triggered in the body, leading to partial disappearance of the tumor, i.e. spontaneous regression.
In our study, we monitored the expression of cytokines in Melanoma-bearing Libechov Minipig (MeLiM) model of hereditary melanoma. We aimed to characterize differences in cytokine expression between MeLiM animals undergoing melanoma progression and spontaneous regression to identify regulatory molecules in these processes and possible markers distinguishing both groups.
RT-PCR and Luminex xMAP assays were used to quantify cytokine expression on mRNA and protein levels in melanoma tissue, normal skin and blood plasma.
Spontaneous regression was characterized by elevated levels of interleukin 12 (IL-12) and cytokines activating IL-1 receptor. In addition, high IL-6 expression was found in melanoma compared to healthy skin, and the effect of recombinant IL-6 on proliferation and migration of MeLiM melanoma-derived cells was studied in vitro.
Our data suggest that the spontaneous regression in MeLiM is accompanied by pro-inflammatory environment supporting recruitment of immune cells. Identified immunoregulatory molecules might find future implications in the research of human disease and therapy.

* Korespondující autor: skalnikova@iapg.cas.cz


This study is supported by the Operational Programme Research, Development and Education (project ID No. CZ.02.1.01/0.0/0.0/16_019/0000785) and by the European Union – Next Generation EU project National institute for cancer research (Programme EXCELES, Project ID No. LX22NPO5102).

Partneři společnosti

LabRules LCMS LabRules GCMS


Bruker HPST Merck Pragolab Amedis EastPort Shimadzu Waters